Plain-English translation of NCT06073470 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand how —a medication commonly prescribed for ADHD—works in children's brains and bodies. This study will give the medication to children with ADHD for 12 weeks, then use brain scans and blood tests to see how it changes brain activity and body chemistry. By comparing children who respond well to the treatment with those who don't, the researchers hope to find a way to predict ahead of time which children will benefit most.
Although this medication is known to help many children with ADHD, doctors can't yet predict which children will respond well and which won't. This study aims to discover biological markers—measurable signs in the brain and blood—that could help doctors personalize treatment and choose the best medication for each child.
You likely qualify if…
You likely don't qualify if…
If you join, you will take the medication for 12 weeks while researchers monitor you. You'll have brain scans (which measure electrical activity) and blood tests done before treatment starts and again after the 12 weeks to see how the medication changed your brain and body chemistry. The study lasts 4 years overall, but your active participation involves the 12-week treatment period with follow-up testing.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Taiwan
Sponsor
National Taiwan University Hospital
Enrollment target
~160 participants
Started
January 2024
Primary completion
December 2027
Age range
6 Years – 18 Years
Last updated on clinicaltrials.gov in March 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chi-Yung Shang, MD, PhD
Department of Psychiatry, National Taiwan University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.